AINewsnow

Superluminal Medicines Raises $60M Series B to Advance Obesity Drug

This story is from 2026-09-03. It is preserved in the archive; the latest stories are on the live feed.

Superluminal Medicines, a Boston biotechnology company applying AI and machine learning to drug discovery, announced on September 3, 2026 the closing of an oversubscribed $60 million Series B financing. BVF Partners, L.P. led the round, which the company said will advance its lead program for rare…

Read the full story at Unite.AI ↗

Timeline · 1 report

  1. 2026-09-03 10:15 · Unite.AI
    Superluminal Medicines Raises $60M Series B to Advance Obesity Drug

More stories

  1. Introducing Kimi K3 on Amazon Bedrock — AWS Machine Learning Blog
  2. Introducing Amazon SageMaker HyperPod Inference Gateway — AWS Machine Learning Blog
  3. Anthropic, OpenAI, SpaceXAI, Google sued over call to ‘pace’ AI development — Politico Technology
  4. Gemini Hacked Three Companies in First Known Breakout by Google’s AI — Wall Street Journal Technology
  5. Alibaba ships Qwen3.8-Omni-Flash to watch, listen and call tools — r/LocalLLM
  6. NVIDIA CEO Jensen Huang rejects ‘AI will end the world’ claim, yet cautions ‘we should go as fast as we can but...’ — Mint AI
  7. Meet the Data Agent in ChatGPT Work — OpenAI YouTube
  8. AI hallucination of Chinese nuclear components almost led to US military attack — Ars Technica AI

Get the daily brief of stories like this at 6:30 every morning →